Multitargeted Self-Replicating RNA for Off-The-Shelf Cancer Precision Immunotherapeutics

Time: 4:30 pm
day: Day Two


  • Replicate Bioscience’s self-replicating RNA platform supports a unique and powerful approach to preventing and reversing the emergence of common acquired resistance mutations
  • Using multigenic self-replicating RNA we have created precision immunotherapeutics that can be dosed in combination with SOC approved cancer agents, thus maintaining selective pressure on the tumour
  • Mechanistically, the combination of the Replicate immunotherapy and the SOC creates a lose-lose situation wherein wild-type tumour clones are controlled by the SOC treatment and resistance mutant positive clones die by the precision immunotherapeutic. We term this synthetic immune lethality